dicted protein sequence revealed little sequence similarity to known proteins or motifs. Further analyses of the human and "mouse genes, particularly with the use of searches of limited regions of 200 to 400 amino acids in length, revealed two similar regions of FMRP that also were similar to 6 repetitive domains in the yeast protein HX and 14 domains of the chicken gene vigillin (VIG) (10) . Alignments of these amino acid sequences and a resulting profile search revealed a number of proteins containing 1 to 14 repeats of an uninterrupted, 30-amino acid domain (Fig. 1A) . Proteins containing this domain, termed KH domains, are believed to constitute a ribonucleoprotein (RNP) family (11) that includes mer1, a yeast protein involved in meiosis-specific alternative splicing (12) ; bacterial polynucleotide phosphorylase, which binds RNA and has phosphorolysis activity (13) ; and the highly conserved ribosomal protein 53 (RP 53) (14) . Thus, most functional aspects of RNA-protein interactions are represented among KH domain-containing proteins, including RNA catalysis, message processing, and translation.
The two KH domains of FMRP reside in the middle of the protein (Fig. 1B) , a Alternative splicing generates several isoforms ofFMRP with a major species of 69 kD (7) . Although predominantly cytoplasmic, occasional nuclear localization is observed (8) . In situ hybridization with FMRJ mRNA reveals widespread but not ubiquitous expression with abundant message present in the testes and in neurons in the brain (9) .
Initial analyses of FMRJ and the pre-2720FIIRED L;G Fragile X syndrome is an X-linked dominant disorder with reduced penetrance that occurs at a frequency of approximately 0.5 to 1.0 per 1000 males and 0.2 to 0.6 per 1000 females (1) . Fully penetrant males exhibit moderate mental retardation along with a phenotype consisting of macroorchidism (enlarged testes), subtle facial dysmorphia, and mild connective tissue abnormalities (2) . Female patients typically are less severely affected, showing little or no somatic signs and only borderline to mild mental retardation. The molecular basis of fragile X syndrome has been attributed to the expansion of an unstable COG trinucleotide repeat in the 5' untranslated region of the gene FMR1 (3. 4). In fragile X syndrome, when the size of the COG repeat is in the affected range beyond 230 repeats, the FMR 1 gene is methylated; this methylation results in transcriptional silencing (5) . The absence of FMR1 message and its encoded protein, FMRP, is believed responsible for the phenQtype of the fragile X syndrome. In addition to the common mutational change of repeat expansion, three variant patients with the clinical presentation of fragile X syndrome have been reported: two males with large deletions encompassing the FMR 1 locus and a severely affected male with a FMR1 lle304-Asn missense mutation (6). ties among all proteins, whereas stippled highlighting indicates similarity between the two KH domains of FMRP. Boldface residues show the positions of polar amino acids, jndicated by f in the consensus sequence The bracketed lysine (K) residues indicate this amino acid at either position in the domain. The position of the isoleucine-to-asparagine mutation at position 304 (13Q4-'ON) in a patient (6) is indicated at the bottom. (8) Diagram of FMRP [residue numbers are as described (7)]. The CGG repeat and initiating codon (M') are indicated as is each KH domain, labeled 1 and 2. Also shown is the amino acid sequence with the two RGG box domains highlighted. Abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, GIy; H, His; I, lie: K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q. Gin: R, Arg; S. Ser; T. (25) . Because the RNA concentration was held constant at 6 nM, a 2:1 stoichiometry of RNA:protein was obtained. Similar studies with RNA from human fetal brain cDNA transcribed in vitro also displayed saturation, but only 1.5 nM FMRP was bound. Considering that the brain RNA was held at a higher concentration of 34 nM, a stoichiometry of approximately 27:1 (RNA:protein) was determined, which suggests that there was selective FMRP binding to approximately 4% by mass of the human fetal brain message. Because FMRI is estimated to account for less than 0.01% of this pool, these data demonstrate FMRP interaction with messages of other human genes.
Biotinylated RNA transcripts from randomly chosen human fetal brain cDNA clones were tested for selective FMRP binding. Analysis of 12 clones identified two that produced RNA that bound to FMRP (Fig. 4) . Insert size appeared unrelated to binding ability, and preliminary sequence analysis of those clones whose RNA bound did not reveal any obvious homology to FMRI cDNA nor to any database sequence. Thus, selective RNA binding of region not involved in alternative splicing (7) . Furthennore, the two FMRP domains show 100% amino acid identity among the human, mouse, and chicken FMRI homologs (15) . In the single patient with severe fragile X syndrome that was a result of a missense FMRl mutation (6), this mutation was in an invariant isoleucine in the 20th position of the second KH domain (Fig. IA) . In addition, FMRP shows two ROO (Arg-Gly-Gly) boxes toward the carboxyl end. ROO boxes are another distinct RNP motif found in heterogeneous nuclear RNP K (hnRNP K) and nucleolar proteins (16).
To biochemically establish and characterize RNA binding by FMRP, we measured 3sS-labeled FMRP bound to biotinylated RNA (17). The 35S-FMRP was translated in vitro from a full-length FMRl complementary DNA (cDNA) (18), which resulted in a 69-kD protein as well as smaller, secondary productS of the reaction ( at approximately 34 kD. Two bands of 33 and 34 kD are predicted based on the FMRP sequence, which confirms that this species is FMRP (21).
The FMRP was able to bind to sense or antisense FMRl RNA (Fig. 2B) . Experiments were performed in the presence of a 62-fold excess of transfer RNA, suggesting that the protein specifically binds to unstructured RNA, perhaps allowing access to the sugar-phosphate backbone and unpaired bases for protein interaction. Ribonuclease (RNase) treatment before streptavidin exposure as well as use of nonbiotinylated RNA resulted in no capture ofFMRP (Fig. 2B) . FMRP binds strongly to singlestranded DNA but to a lesser extent to double-stranded DNA (Fig. 2B) , which is similar to the binding of other RNP family proteins (22). To test whether FMRP binds to all RNA species, we pooled a human fetal brain plasmid cDNA library (23) and performed in vitro transcription in the presence ofbiotin-UTP. A complex mixture of RNAs (average size of 700 base pairs) was produced, some of which allowed the capture of FMRP (Fig. 2B, lane 4) . However, much less RNA binding was observed with the pooled RNAs as compared with that in the presence of FMRI RNA, even with a sixfold molar excess of the former over the latter. Thus, it appears that FMRP is not a general, nonspecific RNA binding protein but rather exhibits some degree of specificity for the RNA species with which it interacts.
As an independent measure of FMRP binding to RNA, a monoclonal antibody (044), which binds specifically to RNA (24), was used (Fig. 2C) . D44 immunoprecipitation of nonbiotinylated RNA with bound FMRP was achieved when protein A-linked agarose beads were used to capture the complex. RNase trearment abolished FMRP capture by this assay as well.
Estimates of the strengrh of the interaction of FMRP with RNA were next oband the amount of biotinylated FMRI RNA Ot biotinylated brain RNA was incteased (Fig. 5B) . Curve fitting with a simple binding equation (26) tesulted in an apparent dissociation constant (Kd) of 5.7 nM for FMRI RNA. When human fetal brain RNA was used, an apparent Kd of 39 nM was obtained. These results were confinned by direct scintillation counting of bound 3SS-FMRP. Substitution of the value for the estimated Kd (5.7 nM) into the equation that described the competition data (Fig. 5A) 
Because the stoichiometry at saturation suggested a 2: I FMRI RNA: FMRP ratio, this possibility is likely. One may also speculate that either the KH or ROO domains, each present tWice in FMRP, are directly binding RNA.
The demonstration that FMRP is an RNA binding protein suggests an avenue of further inquiry as to the precise function of FMRP. Given that the major neurological phenotype of fragile X syndrome is mental retardation, these data provide a means to explore the biochemical basis of cognitive function in humans as well as the pathophysiology of fragile X syndrome. The observation that FMRP interacts with a selective, but substantial, fraction of human brain RNA suggests that other genes, whose products may vary in the absence of FMRP, could playa consequential role in the pleiotropic phenotype of fragile X syndrome.
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FMRP is substantiated, and further analysis of these clones, in conjunction with analysis of FMR1, should allow recognition of any structural RNA detenninants required for FMRP binding.
As would be predicted for saturable binding of FMRP to RNA, competition was observed with nonbiotinylated RNA (Fig.  SA) .0). Aftw a 90-"*' rotaion at 45'C, the cIeaIIed proteV1 was rgeased t1)I healing (3 mil at 1 OO'C) and analyzed t1)I SDS-PAGE, as described (28) PredK:ted hyctoxyIamne ~ sites at resdJes 13,301, arxI 612 of the FMRP seqISK:e (7) (69 kD) and that nine meIhiaines existed in FMRP (7) . the expected nlmber at di9ntegra!kJns per mOUe per of protein was calculated and ad~ted according to the predetem1r1ed efficiency of C(XX1ting (00%) for the isotope. The r1.XTtJer 01 rTdes of rom protein was deterTTined by cIIoidng the 0b-served COlflIs per rrirute of rom protein at saturation by the expected disintegrations per mir1Jte per roe: the coocentration vaI~ given was determined by d~1ng by the reaction volLrne. 28. Biotinyiated RNA binding assays were performed as described by Boelens et al. (17), except that magnetic beads with conjugated strepavidln (Dynal) were used. Captured material was resuspended in 20 ..1 of 1 x SOS sample buffer, and bound protein was eluted by boiling for 10 min and resolved by SOS-PAGE. The 12% SOS-polyacrytamide gels were soaked for 30 min in destain solution (7.5% methanol and 10% acetic acid), followed by 1 hour in 1 M salicylate solution (1 M salicylate, 30% methanol, and 30% glycerol). Gels were then dried and exposed at -BOOC with an intensifying screen for 24 to 72 hours. 29. Biotinylated DNA was prepared with a nick translation kit (Amersham) in the presence of biotinyiated deoxythymk!ine triphosphate (dTTP) (BRL) at an equal molar ratio with dTTP and passed through a G-SO (4) . Another eukaryotic candidate is phytochrome, a plant regulatory protein that has weak but potentially significant similarities to the sequences of bacterial histidine kinases (5) . Histidine kinase activity has been detected in extracts from S. cerevisiae and other eukaryotic cells (6) . This report describes the S. ceretlisiae SLNI gene which encodes a 134-kD product with strong sequence similarities to both the transmitter and receiver domains of the bacterial two-component regulators. We found SLN 1 while studying the N-end rule, a relation betWeen the in vivo half-life of a protein and the identity of its N-terminal residue (7, 8) . The N-end rule is a consequence of a set of ubiquitin-dependent degradation signal called N-degrons (9) . Ubiquitin is a protein whose covalent conjugation to other proteins plays a role in a number of cellular processes, primarily through routes that involve protein degradation (8) . In S. ceretlisiae, the recognition component of the N-end rule pathway is encoded by the UBRI gene (10) . A ubrIA mutant is viable, grows at nearly wild-type rates, but is unable to degrade N-end rule substrates, which are short-lived in wildtype (UBRI) cells (8, 10) .
In a search for the functions of the N-end rule, we carried out a "synthetic lethal" screen to identify mutants whose viability requires the presence of the UBRI gene (11) . To isolate such mutants, termed sIn (synthetic lethal of N-end rule), we used a screen based on 5-fluoroorotic acid (FOA) (12) . In this method, yeast cells lacking ,chromosomal copies of both URA3 and a (nonessential) gene of interest are transformed with a plasmid that expresses both of these genes. The cells are mutagenized and examined for growth on plates containing FOA and uracil. Because FOA selects against URA3-expressing cells (12) , mutants that grow in the absence but not in the presence of FOA should include those whose viability requires the plasmiQ carrying the gene of interest linked to URA3.
A synthetic lethal screen with UBRI yielded a recessive mutant, slnI-I, which was viable in the UBRI but not in the ubrIA background (11) . Our earlier attempts to clone SLNI yielded PTP2, which encodes a putative phosphotyrosine phosphatase, and is an extragenic multicopy suppressor of slnI-I (1 I). The SLNI gene was isolated as described (13) . That the subcloned DNA fragment containing a single open reading frame (ORF) was indeed SLN 1 (rather than an extragenic suppressor of slnI-I) was confirmed by linkage analysis (13) . The 3.66-kb ORF of SLNI encodes a Irene M. ata and Alexander Varshavsky* Many bacterial signaling pathways involve a two-component design. In these pathways, a sensor kinase, when activated by a signal, phosphorylates its own histidine, which then serves as a phosphoryl donor to an aspartate in a response regulator protein. The Sln1 protein of the yeast Saccharomyces cerevisiae has sequence similarities to both the histidine kinase and the response regulator proteins of bacteria. A missense mutation in SLN1 is lethal in the absence but not in the presence of the N-end rule pathway, a ubiquitin-dependent proteolytic system. The finding of SLN1 demonstrates that a mode of signal transduction similar to the bacterial two-component design operates in eukaryotes as well.
mitter domain that acts as a histidinephosphorylating autokinase, when activated by a specific signal. The signal is sensed by a distinct input domain, often located in the periplasmic space. The histidine-linked phosphoryl group of an activated transmitter is transferred to an aspartate in the receiver domain of a response regulator protein, the second component of the pathway. Receiver phosphorylation regulates the activity of its output module, which is often a DNA-binding domain (1-3) .
Although two-component pathways are common in bacteria, evidence for their existence in eukaryotes has been scarce. A protein kinase ftom rat mitochondria has 'To whom correspondence shcxJld be addressed
